Tedizolid: Oral and IV; longer half-life (12 h) so dosed once daily; increased potency versus staphylococci; approved for use in skin and soft tissue infections.
Chloramphenicol Generic, Chloromycetin
Doxycycline Generic, Vibramycin, others
Minocycline Generic, Minocin, others
Tetracycline Generic, others
Azithromycin Generic, Zithromax
Clarithromycin Generic, Biaxin
Erythromycin Generic, others
Clindamycin Generic, Cleocin
Linezolid Generic, Zyvox
Barrera CM et al: Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: A global, double-blind, multicenter, randomized, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet 2016;16:421.
Chopra I, Roberts M: Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232.
De Vriese AS et al: Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006;42:1111.
Dryden MS: Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. 2011;66(Suppl 4):S7.
File Jr. TM et al: SOLITAIRE-IV: A randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis 2016;63:1007.
Hancock RE: Mechanisms of action of newer antibiotics for gram-positive pathogens. Lancet Infect Dis 2005;5:209.
Leclerq R: Mechanisms of resistance to macrolides and lincosamides: Nature of the resistance elements and their clinical implications. Clin Infect Dis 2002;34:482.
Lee M et al: Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508.
Livermore DM: Tigecycline: What is it, and where should it be used? J Antimicrob Chemother 2005;56:611.
Moran GJ et al: Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med 2006;355:666.
Moran GJ et al: Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomized, double-blind, phase 3, non-inferiority trial. Lancet 2014;14:696.
Prokocimer P et al: Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections. JAMA 2013;309:559.
Tasina E et al: Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-analysis. Lancet Infect Dis 2011;11:834.
Van Bambeke F: Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones. Ann Med 2014;46:512.
Wayne RA et al: Azithromycin and risk of cardiovascular death. N Engl J Med 2012;366:1881.